(Q46236872)

English

EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib

scientific article published on 20 November 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

Domenico Galetta

9

object named as

Domenico Galetta

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

author name string

Jian Ming Xu

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

Yu Han

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

Hai Qing Duan

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

E Mei Gao

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

Yang Zhang

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

Xiao Qing Liu

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

Jing Sheng Zhang

7

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

Luca Toschi

8

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

Amalia Azzariti

10

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

Angelo Paradiso

11

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

publication date

20 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

135

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

771-782

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

https://scigraph.springernature.com/pub.10.1007/s00432-008-0512-1

0 references

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-008-0512-1

21 January 2018

Expression of c-erbB3 protein in primary breast carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS00432-008-0512-1

21 January 2018

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The EGF receptor family as targets for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR FISH versus mutation: different tests, different end-points.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2006

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19020901

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-008-0512-1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19020901

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46236872&oldid=2101761776"